Last reviewed · How we verify

autologous dendritic cells with no mRNA transfection

Massachusetts General Hospital · Phase 1 active Biologic Quality 0/100

autologous dendritic cells with no mRNA transfection is a Biologic drug developed by Massachusetts General Hospital. It is currently in Phase 1 development. Also known as: Autologous dendritic cells not transfected with mRNA..

At a glance

Generic nameautologous dendritic cells with no mRNA transfection
Also known asAutologous dendritic cells not transfected with mRNA.
SponsorMassachusetts General Hospital
ModalityBiologic
PhasePhase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about autologous dendritic cells with no mRNA transfection

What is autologous dendritic cells with no mRNA transfection?

autologous dendritic cells with no mRNA transfection is a Biologic drug developed by Massachusetts General Hospital.

Who makes autologous dendritic cells with no mRNA transfection?

autologous dendritic cells with no mRNA transfection is developed by Massachusetts General Hospital (see full Massachusetts General Hospital pipeline at /company/massachusetts-general-hospital).

Is autologous dendritic cells with no mRNA transfection also known as anything else?

autologous dendritic cells with no mRNA transfection is also known as Autologous dendritic cells not transfected with mRNA..

What development phase is autologous dendritic cells with no mRNA transfection in?

autologous dendritic cells with no mRNA transfection is in Phase 1.

Related